Proteaza HIV (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Proteaza HIV" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

15nih.gov

4^th place

8^th place

10doi.org

2^nd place

5^th place

1archive.org

6^th place

9^th place

archive.org

Watkins T; Resch W; Irlbeck D; Swanstrom R (2003). »Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors«. Antimicrob. Agents Chemother. 47 (2): 759–769. doi:10.1128/AAC.47.2.759-769.2003. PMC 151730. PMID 12543689.

doi.org

Davies DR (1990). »The structure and function of the aspartic proteinases«. Annu Rev Biophys Biophys Chem. 19 (1): 189–215. doi:10.1146/annurev.bb.19.060190.001201. PMID 2194475.
Brik A; Wong CH (Januar 2003). »HIV-1 protease: mechanism and drug discovery«. Org. Biomol. Chem. 1 (1): 5–14. doi:10.1039/b208248a. PMID 12929379.
Kräusslich HG; Ingraham RH; Skoog MT; Wimmer E; Pallai PV; Carter CA (1989). »Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides«. Proc. Natl. Acad. Sci. U.S.A. 86 (3): 807–811. doi:10.1073/pnas.86.3.807. PMC 286566. PMID 2644644.
Kohl NE; Emini EA; Schleif WA; in sod. (1988). »Active human immunodeficiency virus protease is required for viral infectivity«. Proc. Natl. Acad. Sci. U.S.A. 85 (13): 4686–4690. doi:10.1073/pnas.85.13.4686. PMC 280500. PMID 3290901.
Seelmeier S; Schmidt H; Turk V; von der Helm K (1988). »Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A«. Proc. Natl. Acad. Sci. U.S.A. 85 (18): 6612–6616. doi:10.1073/pnas.85.18.6612. PMC 282027. PMID 3045820.
McPhee F; Good AC; Kuntz ID; Craik CS (1996). »Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation«. Proc. Natl. Acad. Sci. U.S.A. 93 (21): 11477–11481. doi:10.1073/pnas.93.21.11477. PMC 56635. PMID 8876160.
Jaskólski M; Tomasselli AG; Sawyer TK; Staples DG; Heinrikson RL; Schneider J; Kent SB; Wlodawer A (1991). »Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor«. Biochemistry. 30 (6): 1600–1609. doi:10.1021/bi00220a023. PMID 1993177.
Watkins T; Resch W; Irlbeck D; Swanstrom R (2003). »Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors«. Antimicrob. Agents Chemother. 47 (2): 759–769. doi:10.1128/AAC.47.2.759-769.2003. PMC 151730. PMID 12543689.
Moore JP; Stevenson M (Oktober 2000). »New targets for inhibitors of HIV-1 replication«. Nat. Rev. Mol. Cell Biol. 1 (1): 40–9. doi:10.1038/35036060. PMID 11413488.
De Clercq E (2007). »The design of drugs for HIV and HCV«. Nat Rev Drug Discov. 6 (12): 1001–1018. doi:10.1038/nrd2424. PMID 18049474.

nih.gov

pubmed.ncbi.nlm.nih.gov

Davies DR (1990). »The structure and function of the aspartic proteinases«. Annu Rev Biophys Biophys Chem. 19 (1): 189–215. doi:10.1146/annurev.bb.19.060190.001201. PMID 2194475.
Brik A; Wong CH (Januar 2003). »HIV-1 protease: mechanism and drug discovery«. Org. Biomol. Chem. 1 (1): 5–14. doi:10.1039/b208248a. PMID 12929379.
Kräusslich HG; Ingraham RH; Skoog MT; Wimmer E; Pallai PV; Carter CA (1989). »Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides«. Proc. Natl. Acad. Sci. U.S.A. 86 (3): 807–811. doi:10.1073/pnas.86.3.807. PMC 286566. PMID 2644644.
Kohl NE; Emini EA; Schleif WA; in sod. (1988). »Active human immunodeficiency virus protease is required for viral infectivity«. Proc. Natl. Acad. Sci. U.S.A. 85 (13): 4686–4690. doi:10.1073/pnas.85.13.4686. PMC 280500. PMID 3290901.
Seelmeier S; Schmidt H; Turk V; von der Helm K (1988). »Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A«. Proc. Natl. Acad. Sci. U.S.A. 85 (18): 6612–6616. doi:10.1073/pnas.85.18.6612. PMC 282027. PMID 3045820.
McPhee F; Good AC; Kuntz ID; Craik CS (1996). »Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation«. Proc. Natl. Acad. Sci. U.S.A. 93 (21): 11477–11481. doi:10.1073/pnas.93.21.11477. PMC 56635. PMID 8876160.
Jaskólski M; Tomasselli AG; Sawyer TK; Staples DG; Heinrikson RL; Schneider J; Kent SB; Wlodawer A (1991). »Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor«. Biochemistry. 30 (6): 1600–1609. doi:10.1021/bi00220a023. PMID 1993177.
Watkins T; Resch W; Irlbeck D; Swanstrom R (2003). »Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors«. Antimicrob. Agents Chemother. 47 (2): 759–769. doi:10.1128/AAC.47.2.759-769.2003. PMC 151730. PMID 12543689.
Moore JP; Stevenson M (Oktober 2000). »New targets for inhibitors of HIV-1 replication«. Nat. Rev. Mol. Cell Biol. 1 (1): 40–9. doi:10.1038/35036060. PMID 11413488.
De Clercq E (2007). »The design of drugs for HIV and HCV«. Nat Rev Drug Discov. 6 (12): 1001–1018. doi:10.1038/nrd2424. PMID 18049474.

ncbi.nlm.nih.gov

Kräusslich HG; Ingraham RH; Skoog MT; Wimmer E; Pallai PV; Carter CA (1989). »Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides«. Proc. Natl. Acad. Sci. U.S.A. 86 (3): 807–811. doi:10.1073/pnas.86.3.807. PMC 286566. PMID 2644644.
Kohl NE; Emini EA; Schleif WA; in sod. (1988). »Active human immunodeficiency virus protease is required for viral infectivity«. Proc. Natl. Acad. Sci. U.S.A. 85 (13): 4686–4690. doi:10.1073/pnas.85.13.4686. PMC 280500. PMID 3290901.
Seelmeier S; Schmidt H; Turk V; von der Helm K (1988). »Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A«. Proc. Natl. Acad. Sci. U.S.A. 85 (18): 6612–6616. doi:10.1073/pnas.85.18.6612. PMC 282027. PMID 3045820.
McPhee F; Good AC; Kuntz ID; Craik CS (1996). »Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation«. Proc. Natl. Acad. Sci. U.S.A. 93 (21): 11477–11481. doi:10.1073/pnas.93.21.11477. PMC 56635. PMID 8876160.
Watkins T; Resch W; Irlbeck D; Swanstrom R (2003). »Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors«. Antimicrob. Agents Chemother. 47 (2): 759–769. doi:10.1128/AAC.47.2.759-769.2003. PMC 151730. PMID 12543689.